IMPORTANCE A reduced incidence of microvascular invasion (MVI) in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) may be associated with a decreased risk of early tumor recurrence and better survival after partial hepatectomy. 
A pproximately 70% to 90% of hepatocellular carcinoma (HCC) cases are associated with hepatitis B virus (HBV) infection in the highly endemic Asia-Pacific region.
1,2 Partial hepatectomy and liver transplantation are potential curative treatments for selected patients with HCC. 3, 4 Unfortunately, long-term surgical outcomes remain unsatisfactory because of high tumor recurrence rates. 5, 6 Early HCC recurrence, defined as recurrence within 2 years after partial hepatectomy, has been reported to account for more than 60% of all recurrent HCC events.
7-12 Early recurrence has been associated with the presence of microvascular invasion (MVI), 8, 10, 13, 14 which is a histopathological feature of microscopic metastasis and has been identified in 15.0% to 57.1% of liver resection or transplantation specimens. [15] [16] [17] [18] In contrast, late recurrence commonly arises from a liver remnant with chronic inflammation caused mainly by viral infection and cirrhosis (de novo tumor formation). 8,9 Accordingly, antiviral treatment (AVT) has been reported to reduce late recurrence by suppressing viral replication and inflammation of the liver microenvironment. 8, 9, [19] [20] [21] [22] Experimental studies in 2008 23 and 2010 24 strongly suggested a close association of HBV infection with MVI formation in HBV-related HCC, as HBV infection may augment the angiogenic processes by enhancing the expression of metastasis-associated protein 1. In addition, HBV infection may subvert the immune responses against tumor cells that escape from the primary tumor, thus leading to vascular metastases. 25 Meanwhile, several clinical studies have demonstrated that patients with HBV-related HCC were more likely to develop MVI and microscopic metastasis than patients with HCC with other etiologies, [26] [27] [28] [29] [30] and serum HBV levels might be associated with the extent of vascular invasion. 31, 32 These results suggested the potential association of preoperative AVT with MVI formation and early HCC recurrence. To date, clinical evidence to verify this hypothesis has been lacking. As such, the current study sought to examine the association of preoperative HBV DNA level as well as the use of preoperative AVT with the incidence of MVI and early tumor recurrence among patients with HBVrelated HCC who underwent partial hepatectomy.
Methods

Study Population
The analytic population consisted of 3405 consecutive patients with HBV-related HCC 31,33 who underwent R0 resection between January 2008 and April 2010 at the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China. To clarify the association of HBV infection with long-term surgical outcomes, 853 patients were excluded because of presence of macroscopic vascular invasion (n = 312), preoperative anticancer therapy (n = 284), history of other malignancies (n = 64), concurrent hepatitis C virus antibody positivity (n = 52), perioperative mortality within 30 days of surgery (n = 32), and missing clinicopathological data (n = 109). Data on the remaining 2552 patients were analyzed (eFigure in the Supplement). The study was approved by the Institutional Ethics Committee of the Eastern Hepatobiliary Surgery Hospital. Written informed consent was obtained from all patients for their data to be used for the research.
Preoperative Investigations and Partial Hepatectomy
Routine preoperative investigations included liver function tests, hepatitis B and C antigens/antibodies, α-fetoprotein, abdominal ultrasonography, abdominal contrast-enhanced magnetic resonance imaging or computed tomography, and radiography of the chest. Quantitative analysis of serum HBV DNA level was carried out using polymerase chain reaction (ABI 7300 Real-Time PCR System; Applied Biosystems) with a linear range of quantification of 200 to 2 million IU/mL. The preoperative diagnosis of HCC was based on the criteria of the American Association for the Study of Liver Diseases.
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Partial hepatectomy was considered feasible when patients were in good general condition, all tumor nodules on imaging studies were technically resectable, and the liver remnant functional volume and reserve were assessed to be adequate. The type of hepatectomy was determined by the operating surgeon based on the patient's general performance, tumor stage and location, cirrhosis, and the estimated volume of future liver remnant. An R0 resection was defined as complete removal of macroscopic nodules with a microscopically tumor-free resection margin. 35 The EdmondsonSteiner classification 36 was used to determine the degree of tumor differentiation. Satellite nodules were defined as tumors less than 2 cm in diameter and located less than 2 cm from the main tumor. 37 Microvascular invasion was defined as the presence of tumor cells in a portal vein, hepatic vein, or large capsular vessel of the surrounding hepatic tissue lined by endothelium that was visible only on microscopy.
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Preoperative Antiviral Treatment and Patient Grouping
Preoperative AVT was defined as continuously using at least 1 type of AVT medication for more than 90 days before surgery, which was consistent with the previously reported definition. 39, 40 The selection criteria for AVT were mainly according to the contemporary guidelines for the management of patients with HBV infection. [41] [42] [43] Antiviral agents used in this study are listed in eTable 1 in the Supplement.
Key Points
Question Can antiviral treatment (AVT) affect the incidences of microvascular invasion (MVI) and early tumor recurrence after hepatectomy for hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC)?
Finding In this cohort study of 2362 patients with HBV-related HCC who underwent hepatectomy, a preoperative HBV DNA level of 2000 IU/mL or greater was associated with an increased risk of MVI. Compared with patients who did not receive preoperative AVT, patients who received AVT more than 90 days preoperatively had decreased incidences of MVI and 1-year and 2-year recurrence and less chance to develop recurrences involving multiple hepatic segments.
Meaning Preoperative AVT was associated with a decreased posthepatectomy early tumor recurrence in HBV-related HCC.
Among these 2552 patients, 2036 (79.8%) did not receive any preoperative AVT; 326 (12.8%) met the preoperative AVT criteria, with a median (interquartile range) AVT duration of 23.6 (11.1-40.4) months before surgery. The remaining 190 patients also received AVT before surgery but failed to meet the preoperative AVT criteria. Of these, 13 underwent treatment before HCC diagnosis (8 and 5 received AVT less than 60 and 90 days, respectively), 30 had discontinuous treatment, and 147 received preoperative short-term AVT with a median (interquartile range) treatment duration of 19 (interquartile range, 15-22) days, mainly because of an HBV DNA level of 200 000 IU/mL or greater, which might increase the risks of postoperative hepatitis and hepatic decompensation 44, 45 (eFigure in the Supplement). Among all patients who were treated with AVT before surgery, 475 of 516 (92.1%) received nucleos(t)ide analogues (eTable 1 in the Supplement).
Follow-up and End Points
Patients were followed up once every 2 months in the first 2 years after discharge and then once every 3 to 6 months thereafter. The follow-up regimen, diagnosis, and treatment of HCC recurrence were similar to the management reported previously. 35 In particular, patients who received preoperative AVT were routinely recommended to continue the treatment after surgery. For patients without any preoperative AVT, this treatment was recommended after surgery according to the indication proposed by the related consensus of the same period. [41] [42] [43] In addition, a clear explanation on the need for any long-term medication and on the discontinuation of medication for any reason was given to all the patients who received AVT. On each follow-up visit, the use of medication was verified to assess drug resistance and adverse effects and to adjust medications. The primary end points were overall survival (OS), which was measured from the date of surgery to the dates of patient death or last follow-up, and time to recurrence, which was calculated from the date of surgery to the date when tumor recurrence was diagnosed. Early and late recurrence were defined as recurrent disease developed within or beyond 2 years, respectively, after surgery. [8] [9] [10] [11] The secondary outcome was the presence of MVI on postoperative histopathology.
Statistical Analysis
Categorical variables were compared using the χ 2 test or Fisher exact test. Continuous variables or variables with an abnormal distribution were compared using the unpaired t test or Mann-Whitney U test. Survival curves were calculated and compared using the Kaplan-Meier method and logrank test. Cox regression analyses were used for univariate and multivariate analyses of OS and recurrence. Preoperative factors that might be associated with MVI presence were assessed by univariate logistic regression analysis, and the variables that were significant (P < .05) were subjected in the stepwise multivariate analysis. All analysis was performed using SPSS Statistics version 21.0 for Windows (IBM Corp). A 2-tailed P value less than .05 was considered to be statistically significant.
Results
Patient Characteristics
As shown in Table 1 , among 2036 patients who did not receive any preoperative AVT, 1132 patients with a high viral level (≥2000 IU/mL) were more likely to be positive for hepatitis B e antigen (HBeAg) and had higher levels of alanine aminotransferase and aspartate aminotransferase, a prolonged prothrombin time, cirrhosis, and a surgical resection margin of less than 1 cm compared with 904 patients who had a low viral level (<2000 IU/mL). However, there was no difference in α-fetoprotein level, size and number of tumors, tumor encapsulation, satellite nodules, and tumor differentiation between lowtiter vs high-titer patients. 
Compared with 326 patients who met our preoperative AVT criteria, 2036 patients who did not receive AVT were more likely to be positive for HBeAg; had higher levels of alanine aminotransferase, aspartate aminotransferase, and α-fetoprotein; had larger tumor size; had incomplete tumor encapsulation; and received blood transfusion. Patients who received AVT had a lower platelet count level, prolonged prothrombin time, and cirrhosis. Tumor number, satellite nodules, surgical margin, and tumor differentiation were comparable between patients in the AVT and non-AVT groups. However, patients not receiving AVT had a higher incidence of MVI compared with patients receiving AVT (48.6% [989 of 2036] vs 38.7% [126 of 326]; P = .001) ( Table 1) .
Association of Preoperative HBV DNA Level With the Presence of MVI
To avoid any potential influence of preoperative AVT on the presence of MVI, an analysis was conducted on all 2036 patients not receiving AVT. Multivariate analysis demonstrated that a preoperative HBV DNA level of 2000 IU/mL or greater was an independent risk factor of MVI presence (odds ratio [OR], 1.399; 95% CI, 1.151-1.701), in addition to α-fetoprotein level greater than 400 ng/mL (to convert to micrograms per liter, multiply by 1), increasing tumor size, incomplete tumor encapsulation, presence of satellite nodules, grade III/IV of tumor differentiation, and cirrhosis (eTable 2 in the Supplement).
Association of Preoperative AVT With the Presence of MVI
Subsequent analyses were conducted on all patients receiving and not receiving AVT (n = 2362). Multivariate analysis demonstrated that in addition to a high α-fetoprotein level, large tumor size, incomplete tumor encapsulation, satellite nodules, grade III/IV differentiation, and cirrhosis, an HBV DNA level of 2000 IU/mL or greater was independently associated with an increased risk of MVI (OR, 1.409; 95% CI, 1.171-1.696). In contrast, AVT was associated with a decreased risk (OR, 0.758; 95% CI, 0.575-0.998) ( Table 2 ). The differences in MVI incidence between the AVT and non-AVT groups were also identified in the subpopulations of patients stratified by a tumor diameter of 3 cm or less, 5 cm or less, and 10 cm or less (eTable 3 in the Supplement).
Association of Preoperative AVT With the Presence of MVI Based on Virological Responses
Using the criteria on response to AVT, 46 a Comparison between patients not receiving AVT with a low (<2000 IU/mL) and a high (Ն2000 IU/mL) viral level.
b Comparison between patients not receiving AVT and patients receiving AVT.
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Early Tumor Recurrence and Overall Survival Among AVT vs Non-AVT Groups
The median (interquartile range) follow-up was 44.8 (22.8-59.3) months. For patients receiving AVT, the 6-month, 1-year, and 2-year recurrence rates were 14.2%, 24.6%, and 38.5%, respectively; for patients not receiving AVT, recurrence rates were 23.4%, 37.1%, and 52.3% (P < .001) (Figure, A) . The independent risk factors for early tumor recurrence were analyzed among all 2362 patients in the AVT and non-AVT groups, while the factors associated with late recurrence were assessed among the 989 patients who had a postoperative period of 2 years or more and did not have early recurrence. Multivariate analysis demonstrated that in addition to those factors associated with both early and late recurrences, presence of MVI (hazard ratio [HR], 1.458; 95% CI 1.287-1.652), preoperative AVT (HR, 0.732; 95% CI, 0.605-0.886), α-fetoprotein level greater than 400 ng/mL, surgical margin less than 1 cm, and grade III/IV differentiation were associated only with early recurrence ( Table 3) .
Overall 1-year, 3-year, and 5-year recurrence rates for patients receiving AVT were 24.7%, 50.7%, and 57.9%, respectively; for patients not receiving AVT, recurrence rates were 37.1%, 61.5%, and 70.8% (P < .001). Patients receiving AVT had better survival than patients not receiving AVT, with corresponding 1-year, 3-year, and 5-year OS of 93.1%, 78.9%, and 69.1%, respectively, vs 87.6%, 68.4%, and 56.3% (P < .001) ( Figure Among 1115 patients with MVI, patients receiving AVT had decreased early and overall 1-year, 3-year, and 5-year recurrence rates and better 1-year, 3-year, and 5-year OS rates compared with patients not receiving AVT. Multivariate analysis identified that the use of preoperative AVT was an independent risk factor for both early tumor recurrence (HR, 0.717; 95% CI, 0.548-0.938) and overall recurrence (HR, 0.787; 95% CI, 0.622-0.996). Further stratified analyses showed significant differences in early and overall recurrence between the AVT vs non-AVT groups among all the patients who had an HCC of 10 cm or less (eTable 7 and 8 in the Supplement).
Patterns of Tumor Recurrence Among AVT vs Non-AVT Groups
There were 1329 and 167 patients who had recurrences in the non-AVT and AVT groups, respectively. Although patients not receiving AVT were more likely to develop extrahepatic metastasis than those receiving AVT (8.0% vs 4.2%), overall differences in the type of recurrence were not different between the groups (P = .17). However, patients not receiving AVT were more likely to have multiple intrahepatic recurrent nodules vs those receiving AVT (49.1% [549 of 1119] vs 36.2% [54 of 149]; P = .003). In addition, the sites of intrahepatic recurrence were also different between the non-AVT and AVT groups; recurrences adjacent to the surgical margin or involving multiple segments were more commonly seen in those not receiving AVT than those receiving AVT ( Table 4) .
Outcomes Among Patients Who Underwent AVT Before Surgery But Did Not Meet the Preoperative AVT Criteria
Among 147 patients who received short-term AVT preoperatively, the incidence of MVI was 51.0% (75 of 147), which was higher than the incidence among 326 patients receiving AVT (38.7% [126 of 326]; P = .01) and similar to the incidence noted in patients not receiving AVT (48.6% [989 of 2036]; P = .57).
Recurrences at 6 months, 1 year, and 2 years were 22.5%, 36.3%, and 53.9%, respectively, among these patients, which were higher than the recurrence noted among patients in the AVT group (P = .001) but not different from recurrence noted among the non-AVT group (P = .97).
Discussion
This study demonstrated that a high preoperative HBV DNA level was associated with an increased incidence of MVI in patients with HBV-related HCC. Patients who received consecutive AVT given more than 90 days preoperatively had a decreased incidence of MVI compared with patients who did not receive any preoperative AVT. In addition, preoperative AVT was significantly associated with a decrease in early HCC recurrence after partial hepatectomy. In this study, the association of preoperative HBV DNA level with MVI presence was specifically assessed among patients not receiving AVT. For these patients, any association of preoperative AVT with MVI formation was absent. This result was also not affected by the presence of other risk factors of MVI, such as α-fetoprotein level, tumor stage, tumor encapsulation, and differentiation grade, 17,31,47 as these factors were not different among those not receiving AVT with a high or a low HBV DNA level. The data demonstrated that patients with a high HBV DNA level had an increased incidence of MVI compared with patients who had a low viral level (51.9% vs 44.5%; P = .001). Furthermore, a high viral level was independently associated with an increased risk of MVI presence (OR, 1.399; 95% CI, 1.151-1.701). A, For patients receiving AVT, the 6-month, 1-year, and 2-year recurrence rates were 14.2%, 24.6%, and 38.5%, respectively; for patients not receiving AVT, recurrence rates were 23.4%, 37.1%, and 52.3% (P < .001). B, Overall 1-year, 3-year, and 5-year recurrence rates for patients receiving AVT were 24.7%, 50.7%, and 57.9%, respectively; for patients not receiving AVT, recurrence rates were 37.1%, 61.5%, and 70.8% (P < .001). C, Patients receiving AVT had better survival than patients not receiving AVT, with the corresponding 1-year, 3-year, and 5-year overall survival rate of 93.1%, 78.9%, and 69.1%, respectively, vs 87.6%, 68.4%, and 56.3% (P < .001). There is a lack of evidence supporting an association of preoperative AVT with the presence of MVI and early tumor recurrence. This study demonstrated that patients receiving preoperative AVT had a decreased incidence of MVI compared with patients not receiving AVT (38.7% vs 48.6%; P = .001). Multivariate analysis demonstrated such AVT scheme was significantly associated with a decreased risk of MVI (OR, 0.758 95% CI, 0.575-0.998). In addition, the incidence of MVI was lower among complete responders to AVT compared with those not receiving AVT with a low HBV DNA level (34.9% vs 44.5%; P = .007). Complete response to AVT was a protective factor for the presence of MVI (OR, 0.690; 95% CI, 0.500-0.952).
Previous studies have reported that the importance of preoperative AVT is mainly to reduce postoperative HBV reactivation in patients with HBV-related HCC.
33,44,45 Our data suggested that the association of preoperative AVT with reduced early tumor recurrence as the 6-month, 1-year, and 2-year recurrences, which are often associated with the presence of MVI, were significantly decreased in those receiving AVT vs those not receiving AVT. The presence of MVI was a risk factor for early tumor recurrence (HR, 1.458; 95% CI 1.287-1.652), while AVT was a protective factor (HR, 0.732; 95% CI, 0.605-0.886). In contrast, short-term AVT given before surgery (median [interquartile range] duration, 19 [15-22] days) failed to reduce MVI presence. Accordingly, early recurrence in patients undergoing short-term AVT was similar to that in patients not receiving AVT. Furthermore, the recurrence patterns in patients not receiving AVT were more closely associated with MVI, as these patients were more likely to have intrahepatic multiple recurrences, recurrent nodules involving multiple segments, and extrahepatic metastasis compared with those receiving AVT.
Limitations
Our study has several limitations. First, it is a singleinstitution study. Second, the indication of AVT in patients with HBV infection has been progressively expanded over the past decade, 41-43,48,49 and the importance of AVT in patients with HBV-related HCC has been gradually recognized by surgeons and patients. As such, some patients did not receive AVT during the early period of this study even though they might meet the recent indications for AVT. Third, although short-term preoperative AVT decreased viral levels from 200 000 IU/mL or greater to 20 000 IU/mL or less in 136 of 147 patients (92.5%) before surgery, the incidences of MVI and early tumor recurrence in these patients had not been significantly reduced. Therefore, an optimal preoperative time window for AVT to affect MVI risk remains to be determined. In addition, this study did not provide evidence of the association of preoperative AVT with the tumor-immune microenvironment. Finally, in addition to HBV infection, the biological characteristics of HCC itself may affect the tumor invasiveness and recurrence after surgery.
Conclusions
In conclusion, a high preoperative HBV DNA level had a positive association with MVI formation. Antiviral treatment given more than 90 days before surgery was associated with decreased risks of MVI presence and early tumor recurrence for patients with HBV-related HCC after hepatectomy. Since MVI is also closely associated with tumor recurrence after liver transplantation for HCC, 15 whether pretransplant AVT affects the incidence of MVI in viral-related HCC should be further investigated. Abbreviations: OS, overall survival; AVT, antiviral treatment; MVI, microvascular invasion; HR, hazard ratio; CI, confidence interval; HBeAg, hepatitis B e antigen; AST, aspartate aminotransferase; GGT, gamma glutamyltransferase; ALB, albumin; AFP, alpha fetoprotein.
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